Skip to Main Content

Paper Details

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
116
2021
Author NameAffiliation
Courtney D DiNardoUniversity of Texas MD Anderson Cancer Center
Richard M StoneDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Daniel A PollyeaUniversity of Colorado School of Medicine
Prapti PatelUniversity of Texas Southwestern Medical Center
Hagop KantarjianUniversity of Texas MD Anderson Cancer Center
Martin S TallmanMemorial Sloan Kettering Cancer Center
  • 1 - 7

Datasets

Release 1.2